CLINICAL TRIALS PROFILE FOR PHENTERMINE RESIN 30
✉ Email this page to a colleague
All Clinical Trials for PHENTERMINE RESIN 30
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00000506 ↗ | Cardiovascular System in Obesity: Effect of Treatment | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1983-05-01 | To determine the long-term efficacy of the combination therapy of phentermine and fenfluramine in conjunction with diet, exercise, and behavior modification in the treatment of simple, moderate obesity. |
NCT00402077 ↗ | A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects | Completed | AstraZeneca | Phase 2 | 2006-11-01 | This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects. |
NCT00518466 ↗ | Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults | Completed | VIVUS, Inc. | Phase 1 | 2007-07-01 | The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PHENTERMINE RESIN 30
Condition Name
Clinical Trial Locations for PHENTERMINE RESIN 30
Trials by Country
Clinical Trial Progress for PHENTERMINE RESIN 30
Clinical Trial Phase
Clinical Trial Sponsors for PHENTERMINE RESIN 30
Sponsor Name